Vitreous levels of VEGF, IL-8, and TNF-α in retinal detachment

Current Eye Research

Volumn 35, Issue 6, 2010, Pages 505-509

  Rasier, Rifat ^a   Gormus, Uzay ^a   Artunay, Ozgur ^a   Yuzbasioglu, Erdal ^a   Oncel, Murat ^a   Bahcecioglu, Halil ^a  

^a ISTANBUL BILIM UNIVERSITY   (Turkey)

Author keywords

Interleukin 8; Retinal detachment; Tumor necrosis factor a; Vascular endothelial growth factor

Indexed keywords

INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD RETINA BARRIER; CELL PROLIFERATION; CILIARY DISK; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; EPIRETINAL MEMBRANE; HUMAN; INFLAMMATION; PATHOGENESIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RETINA DETACHMENT; RETINA MACULA HOLE; VITRECTOMY; VITREORETINOPATHY; VITREOUS BODY;

ADULT; AGED; FEMALE; HUMANS; INTERLEUKIN-8; MALE; MIDDLE AGED; OSMOLAR CONCENTRATION; RETINAL DETACHMENT; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTORS; VITREOUS BODY;

EID: 77952517207     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713681003597248     Document Type: Article

References (31)

1. Haimann MH, Burton TC, Brown CK. Epidemiology of retinal detachment. Arch Ophthalmol 1982;100:289-292.
2. Laatikainen L, Tolppanen EM, Harju H. Epidemiology of rhegmatogenous retinal detachment in a Finnish population. Acta Ophthalmol (Copenh) 1985;63:59-64. (Pubitemid 15133731)
3. Törnquist R, Stenkula S, Törnquist P. Retinal detachment. A study of a population-based patient material in Sweden 1971-1981. I. Epidemiology. Acta Ophthalmol (Copenh) 1987;65:213-222. (Pubitemid 17070771)
4. Sasaki K, Ideta H, Yonemoto J et al. Epidemiologic characteristics of rhegmatogenous retinal detachment in Kumamoto Japan. Graefes Arch Clin Exp Ophthalmol 1995;233:772-776.
5. Wong TY, Tielsch JM, Schein OD. Racial difference in the incidence of retinal detachment in Singapore. Arch Ophthalmol 1999;117:379-383.
6. Ah-Fat FG, Sharma MC, Majid MA, McGalliard JN, Wong D. Trends in vitreoretinal surgery at a tertiary referral centre: 1987 to 1996. Br J Ophthalmol 1999;83:396-398.
7. Senger DR, Galli SJ, Dvorak AM et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983-985.
8. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989;161:851-858.
9. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-1309.
10. Tseng W, Cortez RT, Ramirez G, Stinnett S, Jaffe GJ. Prevalence and risk factors for proliferative vitreoretinopathy in eyes with rhegmatogenous retinal detachment but no previous vitreoretinal surgery. Am J Ophthalmol 2004;137:1105-1115.
11. Yoshida A, Yoshida S, Khalil AK, Ishibashi T, Inomata H. Role of NF-kappaB-mediated interleukin-8 expression in intraocular neovascularization. Invest Ophthalmol Vis Sci 1998;39:1097-1106.
12. Kramer M, Goldenberg-Cohen N, Axer-Siegel R et al. Inflammatory reaction in acute retinal artery occlusion: cytokine levels in aqueous humor and serum. Ocul Immunol Inflamm 2005;13:305-310.
13. Aiello LP, Avery RL, Arrigg PG et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-1487.
14. Lutty GA, McLeod DS, Merges C, Diggs A, Plouét J. Localization of vascular endothelial growth factor in human retina and choroid. Arch Ophthalmol 1996;114:971-977. (Pubitemid 26271463)
15. Yuuki T, Kanda T, Kimura Y et al. Inflammatory cytokines in vitreous fluid and serum of patients with diabetic vitreoretinopathy. J Diabetes Complicat 2001;15:257-259. (Pubitemid 32750613)
16. Hernández C, Segura RM, Fonollosa A et al. Interleukin-8, monocyte chemoattractant protein-1 and IL-10 in the vitreous fluid of patients with proliferative diabetic retinopathy. Diabet Med 2005;22:719-722.
17. Armstrong D, Augustin AJ, Spengler R et al. Detection of vascular endothelial growth factor and tumor necrosis factor alpha in epiretinal membranes of proliferative diabetic retinopathy, proliferative vitreoretinopathy and macular pucker. Ophthalmologica 1998;212:410-414.
18. Limb GA, Chignell AH, Green W, LeRoy F, Dumonde DC. Distribution of TNF alpha and its reactive vascular adhesion molecules in fibrovascular membranes of proliferative diabetic retinopathy. Br J Ophthalmol 1996;80:168-173.
19. Limb GA, Hollifield RD, Webster L, Charteris DG, Chignell AH. Soluble TNF receptors in vitreoretinal proliferative disease. Invest Ophthalmol Vis Sci 2001;42:1586-1591.
20. Spranger J, Meyer-Schwickerath R, Klein M, Schatz H, Pfeiffer A. [TNF-alpha level in the vitreous body. Increase in neovascular eye diseases and proliferative diabetic retinopathy]. Med Klin (Munich) 1995;90:134-137.
21. Majka S, McGuire PG, Das A. Regulation of matrix metalloproteinase expression by tumor necrosis factor in a murine model of retinal neovascularization. Invest Ophthalmol Vis Sci 2002;43:260-266.
22. Yossuck P, Yan Y, Tadesse M, Higgins RD. Dexamethasone alters TNF-alpha expression in retinopathy. Mol Genet Metab 2001;72:164-167.
23. Elner SG, Elner VM, Jaffe GJ et al. Cytokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. Curr Eye Res 1995;14:1045-1053.
24. Rodriguez de la Rua E, Martinez V, Aragon J et al. Clinical risk factors for postoperative proliferative vitreoretinopathy (PVR). A prospective study. Arch Soc Esp Oftalmol 2003;78:91-97.
25. Asaria RH, Kon CH, Bunce C et al. How to predict proliferative vitreoretinopathy: a prospective study. Ophthalmology 2001;108:1184-1186.
26. Hooymans JM, De Lavalette VW, Oey AG. Formation of proliferative vitreoretinopathy in primary rhegmatogenous retinal detachment. Doc Ophthalmol 2000;100:39-42.
27. Nagasaki H, Shinagawa K, Mochizuki M. Risk factors for proliferative vitreoretinopathy. Prog Retin Eye Res 1998;17:77-98.
28. Cardillo JA, Stout JT, LaBree L et al. Post-traumatic proliferative vitreoretinopathy. The epidemiologic profle, onset, risk factors, and visual outcome. Ophthalmology 1997;104:1166-1173.
29. Campochiaro PA. Pathogenic mechanisms in proliferative vitreoretinopathy. Arch Ophthalmol 1997;115:237-241.
30. Yanyali A, Bonnet M. [Risk factors of postoperative proliferative vitreoretinopathy in giant tears]. J Fr Ophtalmol 1996;19:175-180.
31. Acar M, Ünlü N, Yilmaz G, Kocaoǧlan H, Aslan B, Duman S. İleri evre proliferatif vitreoretinopatide vitreoretinal cerrahi sonucunu etkileyen faktörler. Türk Oftalmoloji Gazetesi 2002;32:510-515.